Pancreatic Cancer Treatment
Department of Physiology, Pharmacology and Toxicology, Ponce School of Medicine and Health Sciences, Ponce, PR, USA
- *Corresponding Author:
- Kazim Husain, Ph.D. DABT
Professor, Department of Physiology
Pharmacology and Toxicology
Ponce School of Medicine and Health Sciences
P O Box 7004, Ponce, PR 00732, USA
E-mail: [email protected]
Received date: January 27, 2014; Accepted date: February 19, 2014; Published date: February 28, 2014
Citation: Husain K (2014) Pancreatic Cancer Treatment. J Drug Metab Toxicol 5:162. doi: 10.4172/2157-7609.1000162
Copyright: © 2014 Husain K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pancreatic canceris one of the most aggressive and lethal human cancers, with more than 200, 000 deaths worldwide every year. Despite recent efforts, conventional treatment approaches, such as surgery, classic chemotherapy, radiotherapy, biologic therapy and palliative care have only slightly improved patient outcomes. Among the conventional chemotherapies the combination of abraxane (nab-paclitaxel) with gemcitabine and FOLFIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin) with gemcitabine in metastatic pancreatic cancer patients are promising. Among the targeted therapies the combination of gemcitabine, erlotinib and capecitabine are likely to form the base for future treatment. Under biologic or immunotherapy KRAS-targeting vaccines, telomerase-targeting vaccine (GV1001), gastrin-based vaccine, dendritic cell (DC)-based vaccine alone or combined with lymphokineactivated killer (LAK) cells and allogeneic GM-CSF-secreting vaccine (GVAX) are well tolerated by patients and could represent a new therapeutic option for pancreatic cancer. Moreover a novel strategy for using mesenchymal stem cells (MSCs) as means of delivering anticancer genes to the site of pancreas is also encouraging. Current and future clinical trials using natural compounds such as vitamin E compound delta-tocotrienol and curcumin in combination with standard chemotherapy are ongoing to discover more effective ways of treating advanced pancreatic cancer.